ArticleChemistry & biodiversity2026
A Coumarin- and Phthalide-Rich Fraction From Baichuan Baile Formula Alleviates Reserpine-Induced Depression-Like Behaviors by Modulating the Monoaminergic System and Gut Microbiota.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Baichuan Baile (BCBL) is a novel herbal formula composed of three herbs and a food additive with proven antidepressant-like effects. However, its unclear bioactive constituents hinder quality control. This study evaluated BCBL-CP, a fraction extracted via ethanol precipitation and macroporous resin chromatography, mainly comprising coumarins (5-hydroxyxanthotoxin, oxypeucedanin hydrate, byakangelicin) and phthalides (senkyunolides H and I). We rapidly assessed BCBL-CP's efficacy using behavioral despair and 5-hydroxytryptophan-induced head-twitch tests. Subsequently, therapeutic effects on a reserpine-induced depression-like mouse model were evaluated through behavioral assessments. Its effects on the monoaminergic system, cerebral pathology, brain-derived neurotrophic factor (BDNF), and gut microbiota were detected through enzyme-linked immunosorbent assay, hematoxylin and eosin staining, immunofluorescence, and 16S rDNA sequencing. Results showed BCBL-CP exhibited significant antidepressant-like activity in both acute behavioral screening and chronic reserpine-induced depression studies. Mechanistically, BCBL-CP selectively increased prefrontal norepinephrine (p < 0.05), attenuated neuronal damage (p < 0.001), and showed a trend toward BDNF upregulation (p = 0.083). Uniquely, it restored gut microbiota α-diversity (p < 0.01), normalized β-diversity, and modulated eight key bacterial taxa (p < 0.01 or p < 0.05). These findings confirm that these five compounds constitute the major characteristic bioactive constituents of BCBL, providing quality-control markers for developing this prospective antidepressant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.